Healthpeak Properties, Inc. (NYSE: DOC) is a real estate investment trust (REIT) — a company that owns and operates income-producing properties and passes most of its taxable income to shareholders as dividends. The $25 mark has become a focal point because it sits well above the stock's 52-week high of $22.95 and aligns with some of the most bullish targets on Wall Street. In late August, Bank of America raised its price objective on DOC to $25 from $24, keeping a Buy rating — the highest of the recent analyst targets, with others clustered between $22 and $24.
Healthpeak owns, operates, and develops healthcare real estate across the United States, spanning a diversified portfolio of roughly 700 properties. Its two core segments are outpatient medical buildings and life science laboratories, complemented by a smaller mix of senior housing, hospital, and skilled-nursing assets. The company expanded materially in March 2024 by completing its merger with Physicians Realty Trust, strengthening its outpatient medical footprint. Management has also outlined plans to separate its senior-housing assets through an initial public offering of Janus Living, a move intended to sharpen strategic focus and improve cash flow.
Shares of DOC recently traded near $20.82, having climbed from a 52-week low of $15.70 to within roughly 10% of their $22.95 high. The stock offers an annualized dividend of about $1.22 per share, translating to a yield near 5.6% — a meaningful attraction for income-focused investors in a defensive healthcare REIT. As an S&P 500 constituent, DOC is one of the larger healthcare-property landlords, with a market capitalization of approximately $15 billion.
The consensus among the roughly 22 analysts covering the stock is a "Buy," with an average 12-month price target near $23. However, the distribution skews cautious: most recent actions have been "Hold" reiterations. Bank of America ($25) and RBC Capital ($24) carry the most constructive targets, while Barclays ($24) and Morgan Stanley ($22) remain neutral. Morgan Stanley recently downgraded DOC to Equalweight from Overweight on valuation, even as it lifted its target to $22, citing balanced risk-reward given the dividend yield and improved cash flow after the planned Janus Living separation.
For DOC to reach $25, several catalysts would likely need to align. Continued growth in FFO — the preferred earnings measure for REITs because it adds back non-cash depreciation — is central. Morgan Stanley's $22 target is based on a 13x multiple applied to a 2027 FFO estimate of $1.71 per share, implying that a higher share price requires either stronger FFO growth or a higher multiple. A stabilizing or falling interest-rate environment would help, since REIT valuations are sensitive to bond yields. Successfully completing the Janus Living carve-out could also improve the company's growth profile and capital allocation, while ongoing demand for lab and outpatient medical space supports rental income.
The path to $25 is not without obstacles. At current levels, DOC trades at a premium on several valuation measures, and GuruFocus-style fair-value models have suggested the stock may be modestly overvalued relative to its historical multiples. A "higher-for-longer" interest-rate backdrop would keep pressure on REIT valuations broadly. Additionally, the large share of "Hold" ratings indicates that much of Wall Street sees limited near-term upside, and the company carries elevated debt-to-equity leverage relative to some peers, which could constrain growth in a tougher credit environment.
From a technical standpoint, the $22.95 52-week high is the most important resistance level — a prior supply zone where the stock has repeatedly struggled. A sustained close above that level would clear the way toward the psychological $25 mark. On the downside, the round-number $20 area and the mid-teens range near the $15.70 low represent key support zones. The stock's recovery from $15.70 toward $21 signals an intact longer-term uptrend, but the distance to $25 still requires roughly 20% further appreciation.
Investors monitoring whether DOC can reach $25 may also benefit from automated market analysis. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, track existing positions, and identify shifting market trends more efficiently than manual screening alone. Explore the platform to see how these AI-generated signals can complement your research process.
Reaching $25 appears achievable but not imminent for DOC. The strongest case rests on a defensive healthcare portfolio, a healthy dividend yield, FFO growth, and potential value from the Janus Living separation. The primary risks are an elevated valuation, interest-rate sensitivity, and a largely neutral analyst community whose consensus target sits nearer $23. Investors should monitor FFO per share trends, interest-rate developments, the outcome of the Janus Living IPO, and whether the stock can decisively clear its $22.95 resistance level. A break above that prior high, supported by improving fundamentals, would meaningfully strengthen the case for a move toward $25.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, DOC has been closely correlated with IRT. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if DOC jumps, then IRT could also see price increases.
| Ticker / NAME | Correlation To DOC | 1D Price Change % |
|---|---|---|
| DOC | 100% | -0.34% |
| DOC (4 stocks) | 47% Loosely correlated | -0.21% |
| Publishing: Books/Magazines (19 stocks) | 45% Loosely correlated | -0.62% |
| Consumer Services (221 stocks) | 14% Poorly correlated | +0.44% |